OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

Janssen Will Not Seek Regulatory Approval For Erleada P...

(PMLiVE [UK]) Apr 20, 2021 - Johnson & Johnson’s (J&J) pharma division Janssen has announced that it will not pursue regulatory subm...

Genetically Targeted Drug From Syndax Pharma Shows Remi...

(STAT Plus) Apr 20, 2021 - Syndax Pharmaceuticals said Tuesday that its genetically targeted cancer drug induced complete remissions in patien...

Amgen's Investigational Bemarituzumab Receives Breakthr...

(RTTNews) Apr 19, 2021 - Amgen Monday announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation for in...

Featured Content

Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?

Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology...

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discuss clinical progress in bladder cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss clinical progress in Small Cell Lung Cancer (SCLC)

Maintaining oncology practice efficiency is critical in providing optimal care for patients, and leads to a better quality of life for them. At the recent COA conference, oncology stakeholders offered real-life examples and discussed ways to improve patients' overall experience at all stages of cancer, while increasing efficiency and avoiding staff burnou...

Oncology stakeholders discussed their experiences with prescribing biosimilars at the COA annual meeting, noting cost savings but also noting challenges. Shifting payer preferences for preferred therapies resulting in overcrowded pharmacies, and a lack of data and real-world evidence on long-term outcomes and safety were only some of them.

COVID-19 has highlighted health care disparities in the US, leading to poorer survival and outcomes, and gaps in cancer care for racial and ethnic minorities, and the socioeconomically-disadvantaged. COA panelists pinpointed other contributing factors to the inequities, including lack of diversity in both the oncology workforce and clinical trials populat...

Podcasts

Small Cell Lung Cancer (SCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss clinical progress in small cell lung cancer (SCLC)

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

02/28/21

Prostate Cancer - Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

02/22/21

Renal Cell Carcinoma (RCC) - Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcino...

02/22/21

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

01/12/21

Expert Video Insights

Search by

Jorge A. Garcia, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

OBR Green

View Archives

April 2021 Edition

Maintaining oncology practice efficiency is critical in providing optimal care for patients, and leads to a better quality of life for them. At the recent COA conference, oncology stakeho...

April 2021 Edition

Oncology stakeholders discussed their experiences with prescribing biosimilars at the COA annual meeting, noting cost savings but also noting challenges. Shifting payer preferences for p...

April 2021 Edition

COVID-19 has highlighted health care disparities in the US, leading to poorer survival and outcomes, and gaps in cancer care for racial and ethnic minorities, and the socioeconomically-di...

Blog

New Treatment Directions Unveiled at WCLC 2020

Feb 01, 2021

By Ted Bosworth In early stage non-small cell lung cancer (NSCLC), one source of good news at the 2020 World Conference on Lung Cancer (WCLC 2020) was the effi...

ASH 2020 Advances Immunotherapies, Puts Spotlight on He...

Dec 14, 2020

By Mary Ellen Schneider This year’s annual meeting of the American Society of Hematology (ASH) featured new research on chimeric antigen receptor (CAR) T-cel...

DAY 4: Circulating Tumor Cells, HDAC Inhibition, and Ne...

Dec 11, 2020

by Chase Doyle Day 4 of the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual meeting featured advances in early treatment monitoring, a surprising setb...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontelligence^TM and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More